PET has seen rapid progression in recent years, with applications in oncology leading the
way. The glucose analog 18F-FDG is the most commonly used PET radiopharmaceutical …

PET/CT with the glucose analog 18F-FDG has several potential applications for monitoring
tumor response to therapy in patients with non–small cell lung cancer (NSCLC). A …

Integrated positron emission tomography/computed tomography (PET/CT) using 2-[18 F]
fluoro-2-deoxy-d-glucose (18 F-FDG) has emerged as a powerful tool for combined …

The D-glucose analogue 2-(fluorine-18) fluoro-2-deoxy-D-glucose (FDG) is the most
commonly used radionuclide in positron emission tomography (PET) of the thorax …

Despite the increasing use of 18F-FDG PET as a biomarker for predicting therapeutic
response, there are no widely accepted standardized protocols for using 18F-FDG PET as a …

Abstract 18 F-fluorodeoxyglucose (FDG) PET imaging provides physiologic and metabolic
information that characterizes lesions that are indeterminate by CT. FDG PET imaging is …

The d-glucose analog 2-(fluorine-18)-fluoro-2-deoxy-d-glucose (FDG) is the most commonly
used radionuclide in positron emission tomography (PET) of lung cancer. FDG-PET is a …

F18 Fluorodeoxyglucose (FDG) PET/CT is now widely used clinically and has revolutionized
tumor staging, restaging, treatment planning, and prognosis assessment in lung cancer and …

Study objectives 18F-fluorodeoxyglucose (FDG) is the most widely used positron emission
tomography (PET) imaging probe used for the diagnosis, staging, restaging, and monitoring …

PURPOSE: The objective is to validate the combination of 3′-deoxy-3′-[18 F]
fluorothymidine (18 F-FLT) and 18 F-fluorodeoxyglucose (18 F-FDG) as a “novel” positron …